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The  first evidence for tumor-specific antigens came from transplantation studies of 
sarcomas  induced by methylcholanthrene  in inbred mice  (1-5).  Growth  of a  sarcoma 
transplant  in  syngeneic  recipients,  followed  by  its  removal,  increased  resistance  to 
subsequent challenge with the same sarcoma. The surprising feature that emerged from 
the study of these transplantation antigens is that they are distinct for each tumor, no 
two  tumors  having  been  convincingly shown  to  share  the  same  antigen.  Although 
repeated  immunization  with  tumor  cells can  lead to  substantial  resistance  to  tumor 
challenge,  antibody to  the  unique  antigens of chemically induced sarcomas has  been 
difficult to  demonstrate  in  mice  and,  where  positive results  have  been  obtained,  the 
analysis  was  not  sufficiently detailed to  indicate  the  class  of surface  antigen  being 
detected. The fact that murine leukemia virus (MuLV) ~ and its antigens are often found 
in chemically induced sarcomas (6-8) and that normal mouse serum frequently contains 
naturally occurring antibody to MuLV antigens (9-11) adds a serious complication to the 
serological study of these  tumors  and  makes  it virtually impossible to  interpret past 
studies where this was not taken into consideration. Apparently, MuLV-related antigens 
on chemically induced tumors are not effective in eliciting transplantation resistance or 
cross reactions between different sarcomas would have been a far more common finding. 
To initiate a serological analysis of the unique surface antigens of chemically 
induced sarcomas, we have established a number of fibroblast and sarcoma cell 
lines in tissue culture and have defined the surface phenotype of these cells with 
regard to known MuLV and alloantigenic markers. With this background, it has 
been possible  to  characterize a  unique cell surface antigen on Meth A,  the 
widely studied BALB/c methylcholanthrene-induced  sarcoma. 
Materials and Methods 
Animals.  Female mice, 2-5 mo old, were obtained from the following sources: A/Thy-l.1 and 
129 strain mice were from our breeding colony, BALB/c, C57BL/6, and other inbred strains from 
* Supported in part by grants CA-08748 and CA-17404 from the National Cancer Institute. 
Recipient of a fellowship from the Cancer Research Institute, Inc. 
1 Abbreviations used in this paper: FBS, fetal bovine serum; GSCA, Gross cell surface antigen; 
MS, methylcholanthrene sarcoma; MuLV, murine leukemia virus; RDDP, RNA-dependent DNA 
polymerase; TNF, tumor necrosis factor. 
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The Jackson Laboratory, Bar Harbor, Maine, and random bred Swiss ICR from Camm  Research 
Institute,  Inc.,  Wayne, N. J. 
Tumors.  Sarcomas were induced  in  2-mo-old female mice by a  single  subcutaneous injection  of 
0.1 mg 3-methylcholanthrene (Eastman Kodak Co., Rochester, N. Y.) dissolved  in 0.1 ml sesame 
oil. They were maintained by serial  transplantation in the strain of origin or stored in liquid 
nitrogen. With the  exception of  the Meth A and Meth 4 sarcomas, the newly derived sarcomas are 
distinguished by an initial  letter  or letters  indicating their  strain  of  origin (C = BALB/c, B6 = 
C57BL/6,  CB6  =  [BALB/c  x  C57BL/6]F~)  and by the abbreviation  MS  (methylcholanthrene 
sarcoma). 
Meth A was induced in  a BALB/c female mouse in  1960 (5).  An ascites  variant of  the  solid  tumor 
was obtained in 1961 and has been in continuous  in vivo transplantation since that time. The 
original  solid  Meth A sarcoma has been stored  at intervals  in liquid  nitrogen and was used in the 
present studies  during in vivo passages 110-140. 
Meth 4 was induced in a C57BL/6 female mouse in 1972 (12),  and studied during in vivo 
passages 1-10.  CMS1,3,4,5,7,14, and 21 were induced in BALB/c mice in 1975,  and studied during 
in  vivo passages 1-20.  B6MS1,2,4, and 5  were induced in  C57BL/6 mice in  1975,  .and  studied  during 
in vivo passages 1-10.  CB6MS1  and 2 were induced in (BALB/c x C57BL/6)FI mice in 1975,  and 
studied during in vivo passage 1. 
The F9 and PYS culture lines  were derived from a teratocarcinoma  of 129/Sv origin  and were 
provided by Dr. K. Artzt.  The other tumor lines  used in this  study were serially  passaged in mice 
and have been described in previous publications (13-15). 
Culture  Medium.  Eagle's  complete minimum essential  medium was supplemented with 2  mM 
L-glutamine, 1% nonessential amino acids,  100 U penicillin/ml,  100 ~tg  streptomycin/ml, and 10% 
fetal  bovine serum (FBS). 
Cell  Cultures.  Cell  cultures were derived from whole fetuses  (14 days),  lung fibroblasts  of  12- 
to 16-wk-old mice or  transplanted sarcomas as described by Shiku et  al. (12).  Meth A(a) and Meth 
A(s) refer  to culture lines  established from Meth A ascites  and Meth A solid  sarcoma. 
The surface phenotype of  the cultured cells  was determined after  the cells  achieved a stable 
growth pattern in  vitro  and most tests  were conducted on  lines  between the 10th and 30th passage 
generation. 
Antisera to MuLV-Related Antigens and Known Alloantigens. Details  of the serological 
typing systems used for  determining the cell  surface antigens of  fibroblast  and sarcoma cells  are 
given in Table I. The following antisera were used in microcytotoxicity tests:  goat anti-MuLV 
(Rauscher)  p30, goat anti-MuLV  (Rauscher)  gp70, and (W/Fu  ×  BN)F~  anti-W/Fu leukemia 
(C58NT)D = anti-NTD. (The goat antisera were obtained from Dr. R. Wilsnack, Huntington Re- 
search Laboratories, Brookville,  Md.) The specificity  of  these MuLV  antisera has been verified  by 
extensive studies  in our laboratory. 
Antisera to Meth A Antigen.  Two methods of antiserum production resulted in antibody to the 
unique antigen of Meth A sarcoma. The first method involved intraperitoneal injections of 5 x  106 
irradiated  Meth  A  ascites  cells  once  weekly  for  5  wk  in  BALB/c  or  (BALB/c  ×  C57BL/6)F1 
recipients followed by five weekly intradermal challenges of increasing numbers of nonirradiated 
Meth A ascites cells (2 ×  105-1 ×  10  e cells). The second method took advantage of the sensitivity of 
Meth A  sarcoma to the tumor necrosis factor (TNF) present in the serum of Bacillus Calmette- 
Gudrin-infected mice injected with endotoxin (for details of TNF production see reference 25). 
(BALB/c x  C57BL/6)FI mice received 3  x  10  s Meth A  ascites cells injected intradermally. When 
tumors reached approximately 7-8 ram in average diameter, the mice received 0.5 ml TNF + serum 
injected i.v. Approximately 25% of TNF-treated mice showed complete regression of their tumors 
and these animals were  subsequently injected intraperitoneally at 2-wk intervals with viable 
Meth A ascites cells starting with 5 x  10  s and increasing to 5-10 x  l0  s. Mice that remained tumor- 
free through the immunization period were bled individually and their serum titered on Meth A 
ascites cells and Meth A(a) cultured cells. 
Cytotoxic  Tests.  (a) For cells in suspension, the conventional cytotoxic test was used (13, 17, 
26).  (b)  For monolayer cultured cells,  a  modification of the microcytotoxicity test described by 
Bloom was used (27). Monolayer cells were detached with 0.05% Tryptar (Armour Pharmaceutical 
Co., Chicago, Ill.) in Puck's saline A solution, washed in culture medium, and the concentration 
of viable cells adjusted to 2  ×  104 cells/ml in culture medium. A  10-ftl cell suspension containing 
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TABLE  I 
Description of Serological Typing Systems for Detecting Cell Surface Antigens of 
Fibroblast and Sarcoma Cell Lines by Absorption Tests 
Complement 
Antigenic  Antiserum  Standard test  cell  source (serum  Reference 
system  (dilution)*  dilution) 
MuLV-Related 
antigens 
G~x  Rat (W/Fu  ×  BN)F~ anti-  129 thymocytes  Rabbit  16, 17 
W/Fu leukemia  (1:12) 
(C58NT)D (anti-NTD) 
(1:150) 
GCSA  C57BL/6  anti-transplanted  E c~G2 leukemia  Guinea pig  13 
spontaneous AKR leuke-  cells  (1:2) 
mia K36 (1:10) 
Alloantigens 
H-2.2  (BALB/c  x  HTI)FI  anti-  C57BL/6  lymph  Guinea  pig  18 
(H-2D  b)  EL4 (1:10)~  node cells  (1:4) 
H-2.33  (B10.A x HTG)FI anti-EIA  C57BL/6  lymph  Guinea  pig  18 
(H-2K  b)  (1:60)$  node cells  (1:4) 
H-2.4  BALB.G anti-BALB/c  BALB/c  lymph  Guinea  pig  18 
(H-2D  d)  (1:10)$  node cells  (1:4) 
H-2.31  (A  x  BALB.B)FI  anti-  BALB/c  lymph  Guinea  pig  18 
(H-2K  d)  BALB/c (1:20)$  node cells  (1:4) 
Ia.7  A.TH anti-A.TL (1:20)§  BALB/c  lymph  Guinea pig  19, 20 
node cells  (1:4) 
Lyt-l.2  C3H  anti-CE  thymocytes  C57BL/0thymo-  Rabbit  21, 22 
(1:50)  cytes  (1:15) 
Lyt-2.2  (C3H  x  B6-Ly-2.1)F1 anti-  C57BL/6  thymo-  Rabbit  21, 22 
ERLD  (1:100)  cytes  (1:15) 
PC.1  (DBA/2 x C57BL/0)FI anti-  MOPC-70A  Guinea  pig  15 
MOPC-70A  (1:8)  (1:2.5) 
Thy-l.2  (A-Thy-l.1  x AKR-H-2b)F~  A thymocytes  Rabbit  22, 23 
anti-ASL1 (1:160)  (1:15) 
TL.2  (A-TL- x  C57BL/6)F~ anti-  BALB/c thymo-  Rabbit  24 
ASL1 (1:400)  cytes  (1:15) 
* Dilution used for  absorption tests. 
$ Obtained from Dr. F. Lilly,  Albert Einstein College of  Medicine, New York. 
§ Obtained from Dr. D. C. Schreffler,  Washington University Medical School, St. Louis,  Mo. 
Inc., Whittier, Calif.)  or a 1-ml disposable glass  syringe (no. 704S, Beckton-Dickinson &  Co., 
Rutherford, N. J.) into  the wells of  Falcon Microtest Plates (no.  3034,  Falcon Plastics  Division of 
BioQuest, Oxnard, Calif.).  The plates  were then incubated at  37°C in  5% COs in humidified air  for 
18  h. Medium was removed by  blotting  with a gauze sponge, and 10/~l  of  the appropriate dilution 
of  antiserum and 10/~l selected  rabbit serum (1/20-I/30)  as complement source (each diluted in 
cultured medium with 10% heat inactivated FBS) were added. After further incubation for 18 h, 
the  plates  were again blotted  with gauze sponge, fixed  with absolute methanol, and stained with 
2% Giemsa stain (Fisher Scientific  Co.,  Pittsburgh, Pa,) in 0.08  M  sodium phosphate buffer (pH 
7.2). 
For  analysis  of  the  Meth A antigen, sensitization  with  antiserum before  addition  of  complement 
augmented cytotexicity  and resulted in higher antiserum titers.  Thus in all  tests  recorded here, 
cultured Meth A(a) cells  were presensitized  with antiserum for  30 rain  at  37°C in 5% COs in hu- 
midified air.  Antiserum was then removed with a gauze sponge and complement was added fol- 
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Fzo.  1.  Microcytetoxicity tests for MuLV-related antigens on flbroblast and sarcoma cell 
lines of BALB/c and C57BL/6 (B6) origin. 
Tests were performed in duplicate along with appropriate media, antiserum, and complement 
controls. Plates were analyzed microscopically and the percentage cytotoxicity of a given antise- 
rum dilution was calculated as follows: 
cytotoxicityPercent =  [1 -  number~eHOf  cells in well treated~withw~antiserum~  ~and  complement  1~  J  × 100. 
Antisera controls showed -  5% cytotoxicity and complement controls were in the range of 5-15% 
cytotoxicity. 
Absorption Tests.  These were performed according to methods developed in our laboratory (13, 
17, 26). The dilution of antiserum chosen for absorption tests was generally two doubling dilutions 
below its end point  (50% cytotoxicity), as determined in preliminary tests.  Equal volumes of 
diluted antiserum and packed washed cells were incubated together, with frequent shaking, for 30 
min at 4°C. After removal of  the absorbing cells by centrifugation, the residual cytotoxic activity of 
the serum was tested. Monolayer cells were harvested for absorption tests by treating cultures 
with 0.05% EDTA. 
XC Plaque Assay for Ecotropic MuLV.  Culture fluids were tested by the method of Rowe et al. 
(28). 
RNA-Dependent DNA Polyrnerase (RDDP) Assay.  Culture fluids were tested by the method of 
Stephenson et al. (29). 
Results 
MuL  V Expression by Cultured Fibroblasts and Sarcomas.  The cultured cell 
lines were assayed for MuLV expression by (a) microcytotoxic tests with polyva- 
lent  anti-MuLV serum  (anti-NTD)  and  with  antiserum  to  MuLV  structural 
components gp70 and p30 (Fig.  1), (b) absorption tests for two type-specific cell 
surface antigens specified by MuLV, G~, and Gross cell surface antigen (GCSA) 
(Fig.  2).  (c) XC assays for infectious MuLV ecotropic virus and (d) assays for 724  CELL  SURFACE  ANTIGENS  OF  SARCOMAS  OF  THE  MOUSE 
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FIG.  2.  Typing of BALB/c fibroblast and sarcoma cell lines for GCSA and C~x cell surface 
antigens by absorption tests. E 6 G2, a GCSA  + MuLV (Gross)-induced leukemia of C57BL/6 
origin, and AKR thymocytes, a  G~x + cell population, were included as positive control cells. 
RDDP.  Table II summarizes the results of these tests for MuLV and MuLV- 
related antigens. 
Cell lines of BALB/c origin could be classified MuLV- or MuLV  ÷ on the basis 
of these several assays, and the expression of MuLV antigens invariably corre- 
lated with the presence of infectious MuLV and RDDP activity. In contrast, cell 
lines of C57BL/6, A and (BALB/c x  C57BL/6)F1  origin reacted with anti-gp70 
even though they showed no other evidence of MuLV infection. Mice of these 
strains are known to express a gp70 molecule on the surface of their cells that is 
not dependent on productive MuLV infection (30). This selective expression of a 
portion of the viral genome is not seen with BALB/c cells, where either the full 
range  of MuLV  gene  products  were  present  or  no  viral  markers  could  be 
detected. 
In this study, 6 of the 11 lines of sarcoma cells typed MuLV  + by all assays. 
This does not appear to relate to length of time these tumors were passaged in 
vivo before tissue culture. For example, the line derived from the long-trans- 
planted Meth A ascites (Meth A(a)) was MuLV-, whereas CMS1 and CMS3 of 
more recent derivation were MuLV  +. No discernible difference in the growth or 
morphology of MuLV  + or MuLV- sarcoma cells was evident. 
With  regard  to  the  stability of the  MuLV phenotype of culture  lines,  11 
sarcoma cell lines were repeatedly tested over a  10-mo period with consistent A.  B.  DeLEO,  H.  SHIKU,  T.  TAKAHASHI,  M.  JOHN,  AND  L.  J.  OLD  725 
TABLE  II 
Expression of MuLV and MuLV-Related  Antigens by Fibroblast and Sarcoma Cell Lines: 
Summary of Results 
Direct  microcyto-  Absorption 
toxicity  tests  tests  XC  Assay  for 
Strain  Cell line  ecotropic  RDDP 
Anti-  Anti-  Anti-  MuLV  Assay 
Gix  GCSA 
NTD  p30  gp70 
BALB/c 
C57BL/6 
(BALB/c  x 
C57BL/6)FI 
Fetal  fibroblasts  ...... 
Adult  lung  fibro  ........ 
blasts  (I) 
Adult  lung  fibro-  +  +  +  +  +  +  + 
blasts  (II) 
CMS1  sarcoma  +  +  +  +  +  +  + 
CMS3  sarcoma  +  +  +  +  +  +  + 
CMS4  sarcoma  ....... 
CMS5  sarcoma  ....... 
Meth  A(a)  sar ........ 
coma 
Meth  A(s)  sar-  +  +  +  +  +  +  + 
coma 
Fetal  fibroblasts  -  +  .... 
Adult  lung  fibro-  -  -  +  .... 
blasts 
Meth  4  +  +  +  +  +  +  + 
B6MS2  sarcoma  +  +  +  +  +  + 
B6MS5  sarcoma  -  +  .... 
CB6MS1  sarcoma  -  +  -  - 
CB6MS2  sarcoma  +  +  +  +  + 
A  Adult  lung  fibro- 
blasts 
+ 
results. One BALB/c fibroblast line, however, showed a spontaneous MuLV- to 
MuLV  ÷  conversion  after  6  mo  in  tissue  culture.  This  was  accompanied  by 
changes  associated  with  transformation  (i.e.,  more  rapid  growth  rate  and 
greater saturation density of the cultured cells). 
Cell Surface Alloantigens of Cultured Fibroblasts  and Sarcomas.  The fibro- 
blast and sarcoma cell lines were typed for known cell surface alloantigens by 
absorption tests. Table III summarizes these results.  (Because the typing anti- 
sera contain antibody to MuLV-related antigens,  MuLV  ÷ cell lines cannot be 
typed in direct cytotoxic tests. This does not interfere, however, with typing by 
absorption.) 
H-2D AND H-2K ALLOANTIGENS.  All cell lines expressed the appropriate H-2D 
and H-2K private specificity. 
Thy 1.2.  Fig.  3  illustrates  absorption  tests  for  Thy-l.2.  AKR  thymocytes 
(phenotype Thy-l.1) and  B6 thymocytes (phenotype Thy-l.2) were included as 
negative and positive control cells. On the basis of these tests, fibroblasts and 
sarcoma cells can be clearly typed Thy-l.2- or Thy-l.2 ÷. 726  CELL  SURFACE  ANTIGENS  OF  SARCOMAS  OF  THE  MOUSE 
TABLE III 
Cell Surface Alloantigens of Cultured Fibroblast and Sarcoma  Cell Lines as Determined  by 
Absorption  Analysis: Summary of Results 
Strain  Cell  line  H-2.4  H-2.31  H-2.2  H-2.33  Thy-l.2  PC.1  Lyt-l.2  Lyt.2.2  Ia.7  TL.2 
(H-2D  d)  (H-2K  d)  (H-2D  b)  {H°2K  b) 
BALB/c  Adult  lung  fibro-  +  +  -  +  +  -  -  - 
blasts  (I) 
Adult  lung  fibro-  +  +  -  -  +  +  - 
blasts  (II) 
CMS1  sarcoma  +  +  ..... 
CMS3  sarcoma  +  +  -  +  .... 
CMS4  sarcoma  +  +  -  +  -  - 
CMS5  sarcoma  +  +  -  +  ..... 
Meth  A(a)  +  +  ....... 
Meth  A(s)  +  +  -  -  +  .... 
C57BL/6  Adult  lung  fibro-  -  +  +  +  ..... 
blasts 
B6MS2  -  -  +  +  ...... 
Meth  4  -  +  +  ...... 
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FIG.  3.  Typing of BALB/c fibroblast and sarcoma cell lines for Thy-l.2 and PC.I alloanti- 
gens by absorption tests. C57BL/6 (B6) thymocytes (Thy-l.2 +) and AKR thymocytes (Thy- 
1.2-) were  included as control cells for Thy-l.2 tests.  BALB/c liver (PC.1 +) and B6 liver 
(PC.l-) were included as control cells for PC.1 tests. 
PC.l.  Fig.  3  illustrates  absorption  tests  for  PC.1.  B6  liver  (PC.l-)  and 
BALB/c liver (PC. 1  +) were included as negative and positive absorbing tissues. 
Two BALB/c lung fibroblast lines and Meth A(s), the cell line derived from the 
solid Meth  A  sarcoma,  typed  PC.1 +.  In contrast,  Meth A(a),  the line derived 
from the Meth A  ascites tumor, was PC.l-. A.  B.  DELED,  H.  SHIKU,  T.  TAKAHASHI,  M.  JOHN,  AND  L.  J.  OLD 
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FIG. 4.  Microcytotoxicity  tests of (BALB/c x  C57BL/6) anti-Meth A serum on MuLV- 
fibroblast and sarcoma cell lines of BALB/c  origin. 
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TL.2,  LYT-1, LYT-2, Ia-7.  These  alloantigens  were  not  demonstrable  on  any 
fibroblast or sarcoma cell line. 
The Meth A  Antigenic System.  A  number of syngeneie antisera have been 
prepared  against  individual  BALB/c or C57BL/6 sarcomas.  Regardless of the 
MuLV phenotype of the immunizing sarcoma, the resulting antisera invariably 
contained cytotoxic antibody to MuLV-related antigens and were reactive with 
MuLV  + fibroblast or sarcoma cell lines. Because of this, our search for sarcoma- 
specific antigens  focuses on  MuLV-  sarcoma  lines  of BALB/c origin  so that 
reactions due to MuLV antibody will not confound the serological analysis. The 
first antigen to be defined in this way is the unique antigen of Meth A sarcoma. 
DIRECT CYT(Y~XIC TESTS WITH METH A ANTISERA.  Antisera  prepared  in BALB/c 
or (BALB/c x  C57BL/6)F1 mice by repeated inoculations of Meth A ascites cells 
were cytotoxic for Meth A ascites cells as well as for the MuLV- tissue culture 
line derived from Meth A ascites sarcoma. The antisera had little or no cytotoxic 
activity for other MuLV- cultured cells of BALB/c origin (Fig. 4). 
ABSORPTION ANALYSIS OF METH A ANTISERA.  Fig. 5 illustrates absorption tests 
with Meth A  antisera  and Table IV summarizes  the results  of the extensive 
absorption analysis  that  defines the Meth A  system.  The  Meth A  antigen  is 
restricted to the ascites and solid forms of Meth A sarcoma and the culture lines 
derived from them. It has not been found on any other normal or neoplastic cell 
type. 
TESTS FOR METH A ANTIGEN ON NORMAL LYMPHOID  CELLS.  It has recently been 
suggested that the transplantation  antigens of chemically induced tumors rep- 
resent derepressed or altered products of the 11-2 complex (31-33). The absorp- 
tion tests summarized in Table IV give no support to the idea that the Meth A 
antigen  is related to histocompatibility antigens  normally expressed by other 
mouse strains, since the spleen cells of 14 different inbred strains lacked Meth A 
antigen. These strains represent six independent H-2 haplotypes and the major- 
ity of known private  and public specificities defined by the I1-2  complex.  To 728 
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(a)  (b) 
Positive  Negofive  Positive  Negative 
Absorptions  Absorptions  Absorptions  Absorptions, 
o  Meth Aascltes  z~  CMS I  o  MethA ascites  ~  BALB/c  MOPC-70A 
•  MethAsolid  {3  CMS5  eMethA(o)  •  BALB/c  RLO'I 
•  MethA(o)  v  CMS7  v  ASLI 
•  CMS 14  x  RADA  I 
•  CMS21  •  K  36 
•  EARAD I 
Ed' G2 
<Un%besr°~ed 
4'0  '  40  '  6~,o' 
~.  Unobsorbed  ~ 
"  Serum 
@--o  --o--...-~--o 
4b  '  ~o  '640  ' 
I/Dilution of Absorbed  Antiserum 
(c) 
Positive 
Absorption 
(I  Meth A (o) 
Negofive 
Absorptions 
x  BALB/c 
v  (BALB/c xB6)F1 
o  LP  •  SWR 
~,  SJL 
•  AKR 
c]  A 
•  NZB/BI 
~Ix~,~  ?~berS°~Ded 
4  80  160  320 
FIa.  5.  Absorption analysis of (BALB/c  x  C57BL/6)F,  anti-Meth A  serum. (a) tests with 
BALB/c  sarcomas passaged  in vivo,  (b) tests with syngeneic  and allogeneic leukemia and 
myeloma cells and (c)  tests with syngeneic  and allogeneic  normal spleen cells.  Absorbed 
antisera assayed for residual cytotoxicity on Meth A(a) cultured cells. 
exclude the possibility that the Meth A absorption system detects more than one 
determinant and that normal cells express only one of them and therefore fail to 
absorb Meth A reactivity, the Meth A antiserum was tested for direct cytotoxic- 
ity on normal lymphoid cells from spleen and thymus.  No cytotoxic reactions 
were observed with cells from the following strains of mice: A, BALB/c, BI0.A, 
C3H/An, C57BL/6,  RF, PL, SJL, Swiss, SWR, and 129. 
Discussion 
In  contrast  to the  detailed  knowledge  we have  of the  surface  antigens  of 
normal and neoplastic lymphoid cells of the mouse (34), far less is known about 
the antigens that characterize the surface of fibroblast and sarcoma cells. The 
greater  sensitivity  of lymphoid  cells  to  cytotexic  antibody  and  the  ease  of 
working with cells that remain in free suspension (rather than with cells like 
fibroblasts  that  adhere  to  glass)  clearly  account  for  the  past  emphasis  on 
lymphoid populations. Serological analysis of lymphocytes, particularly those of 
thymic derivation, has uncovered a series of surface antigens that are restricted 
to cells that have undergone this pathway of differentiation (hence the designa- 
tion differentiation antigens to distinguish antigens that characterize different 
cell  populations).  Alloantigens  belonging  to  the  Lyt  family,  of which  four 
separate systems have now been defined and several others identified but not as 
yet analyzed, are prime examples of differentiation antigens on T lymphocytes 
(35). The presumption is that these surface molecules play a critical role in the 
interactions involved in differentiated cellular function and that all specialized 
cell types will be marked by a uniquely characteristic display of surface anti- T
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gens. Whether this conclusion can be extended to other cell populations is now 
the subject of considerable interest.  Because the fibroblast establishes itself in 
vitro with relative ease and can be derived from different organs and from mice 
of different  ages,  it  is  a  particularly  attractive  model  for  such  studies.  In 
addition, as much of our current thinking about malignant transformation has 
come from in vitro studies with fibroblasts, the development of a comprehensive 
serology for  the  cell  surface  antigens  of fibroblasts  would  provide  valuable 
immunogenetic  probes with  possibly greater  resolving power than  lectins  to 
analyze the surface modifications that accomp~my the malignant change. 
With the widespread occurrence of MuLV in the mouse, the possible contribu- 
tion  of MuLV antigens  must  always be considered  in  interpreting  results  of 
immunological analysis of mouse cells, whether normal or malignant,  and this 
is true whether one is working with serological techniques or those measuring 
cell-mediated immunity. Although it has been known for some time that sarco- 
mas induced by chemical carcinogens may express cell surface antigens related 
to MuLV, this has not been the subject of any detailed study. Before attempting 
to define new surface alloantigens or tumor-specific antigens on sarcoma cells, it 
is essential to characterize the MuLV phenotype of the target  cell.  All mouse 
serum,  whether from immunized  donors or not,  must be suspected of having 
antibodies to surface MuLV antigens, and we have not as yet found any reliable 
or routine  method to eliminate  them.  Cells expressing  MuLV are,  therefore, 
generally unsuitable as target cells for detecting non-MuLV antigens in direct 
cytotoxic tests; positive reactions with mouse sera may be due to the presence of 
MuLV antibody and appropriate  absorption tests are necessary to resolve the 
issue of specificity. For this reason,  the availability of MuLV- fibroblast and 
MuLV- sarcoma lines greatly facilitates search for surface antigens unrelated to 
MuLV. 
What significance can be attributed to the appearance of MuLV in sarcomas 
arising in strains  (such as BALB/c) that normally do not express these endoge- 
nous viral genes? Does it reflect the general tendency of malignant cells to show 
instability in genetic control of the differentiated state, resulting in the activa- 
tion of ordinarily  silent genes,  or is it of etiological significance,  with MuLV 
playing a critical role in chemical carcinogenesis, a suggestion that continues to 
attract attention? The fact that some sarcomas express MuLV and others do not, 
even  though  they all  presumably  carry  MuLV  genes,  indicates  that  MuLV 
activation is not an invariable consequence of malignant transformation.  Nor is 
MuLV  activation  restricted  to  sarcomas,  since  ~.ome morphologically  normal 
fibroblast lines  become MuLV  ÷ during  passage  in tissue  culture.  In BALB/c 
mice, full expression of the viral genes and the antigens they determine appears 
to be the case under conditions of MuLV activation. Thus, the surface phenotype 
of MuLV  + sarcoma or fibroblast lines is G~ + GCSA  + gp70  + p30  +. We did not find 
any instance of partial expression of MuLV (e.g., G~  + GCSA-) as if only part of 
the viral genome was activated. In contrast, C57BL/6 fibroblasts and sarcomas 
carry a  gp70-1ike molecule on their surface, whether they express other MuLV 
traits  or not.  This  gp70 of C57BL/6 cells is  most likely related  to the  0-gp70 
molecule that  has been detected on normal  C57BL/6 lymphoid and leukemia 
cells (30) and appears to be the product of a separate MuLV locus in this strain. 
With  the  recognition  that  there  is  far  more  MuLV  polymorphism  than  was A.  B.  DeLEO,  H.  SHIKU,  T.  TAKAHASHI,  M.  JOHN,  AND  L.  J.  OLD  731 
originally suspected, it will be important to characterize the MuLV from fibro- 
blast and sarcoma cultures to determine  whether they can be distinguished from 
MuLV derived from normal or leukemic lymphoid tissues. 
Of the differentiation alloantigens studied, Thy-1 and PC.1  have been de- 
tected on some fibroblast and sarcoma cell lines.  These antigens may not be 
stable markers for cultured fibroblasts since we have observed the loss of Thy-1 
and PC.1  from fibroblast cultures that in earlier passages typed Thy-1  + and 
PC.I + by absorption. Another explanation for this finding could be that fibro- 
blasts are dimorphic for these alloantigens and that the emergence  of Thy-1- or 
PC.I-  cultures represents the outgrowth of one cell type from an originally 
mixed population. Either explanation (instability and loss of antigen expression 
in vitro or dimorphic populations of normal fibroblasts) could account for the 
finding of Thy-1  + or-  and PC.I + or-  sarcoma lines.  As expected, alloantigens 
belonging to the TL and Lyt systems that characterize cells of thymic origin 
were not detected on fibroblast or sarcoma cells.  Given this  information on 
known alloantigens, it should be possible to develop a series of  planned immuni- 
zations in mice of various genotypes to uncover new surface alloantigens of 
fibroblasts and sarcoma cells. 
A  remarkable and baffling feature of chemically induced sarcomas is  the 
extensive range of antigens that have been detected by transplantation immu- 
nity in syngeneic mice.  Since the  discovery of this class of tumor antigens, 
sarcomas induced by a variety of chemical carcinogens have been the object of 
intense scrutiny by tumor immunologists and yet not a single instance of a bona 
fide sharing of antigen by two tumors, even when induced in the same mouse 
(36), has been established. There has been much discussion concerning the basis 
of this extensive antigenic diversity. Whether these unique surface antigens 
have their origin in carcinogen- or malignancy-induced  changes in structural or 
regulatory genes, or arise from epigenetie errors in membrane synthesis is not 
known. Clearly, their analysis would be greatly facilitated if serological meth- 
eds for detecting them were devised. The present study of BALB/c Meth A 
sarcoma represents an attempt to define serologically  the strong transplantation 
antigen carried by this tumor. The availability of an aseites variant of this 
tumor was particularly useful, providing an abundant source of cells for immu- 
nization and a target cell population for cytotoxic tests with >95% viability that 
does not require removal of dead cells by proteolytic enzymes. Another advan- 
tage is that Meth A ascites (in contrast to the original solid tumor) does not 
express MuLV antigens, and cultured lines derived from it remain MuLV-. The 
disadvantage of this system, of course, is that Meth A is a  long-transplanted 
tumor that has had ample time to diverge from the strain of origin during the 17- 
yr since its induction. However, as the original solid tumor and the ascites 
variant which have had a separate passage history for the past 16 yr continue to 
share the same antigen, this would indicate a high degree of coding stability for 
Meth A antigen. Nevertheless, the conclusions derived from the study of Meth A 
will have to be confirmed with a series of newly derived sarcomas. 
Absorption analysis has not as yet given any clues regarding the origin of the 
Meth  A  antigen.  There has  been  speculation that  the  specific antigens  of 
chemically induced tumors and other tumors  as  well might represent dere- 
pressed fetal antigens, modified antigens of the 1-1-2 complex, or derepressed 732  CELL  SURFACE  ANTIGENS  OF  SARCOMAS  OF  THE  MOUSE 
alloantigens (e.g., anomalous appearance of TL antigens in leukemias of TL- 
strains  [34]). Another  possibility in  view  of the  extensive polymorphism of 
MuLV is that MuLV genetic information (e.g., from recombinational or muta- 
tional  events)  might  be  responsible  for  the  unique  antigens  of chemically 
induced tumors. The fact that no other normal or malignant tissue, adult or 
fetal,  MuLV  +  or  MuLV-,  expressed  Meth  A  antigen  provides  no  help  in 
distinguishing these possibilities. Biochemical characterization of Meth A anti- 
gen now that serological reagents are available may be more revealing. 
Summary 
As background for a  serological definition of the unique antigens of chemi- 
cally induced sarcomas, we have typed a  series of fibroblast and sarcoma cell 
lines of BALB/c and C57BL/6 origin by cytotoxicity and absorption tests for 
murine leukemia virus (MuLV)-related cell surface antigens and known alloan- 
tigens.  7 of the 17 cultured lines expressed the range of cell surface antigens 
associated with MuLV (G~x, GCSA, gp70, p30),  and this was invariably associ- 
ated with MuLV production. In nonproducer lines of C57BL/6 (but not BALB/c) 
origin, a MuLV-gp70-1ike molecule was found on the surface of fibroblasts and 
sarcoma cells.  The alloantigenic phenotype of these MuLV  + and MuLV- cell 
lines was H-2D  +, H-2K  +, Thy-l.2  +°r -, PC.1 + or-, Lyt-l.2-, Lyt-2.2-, Ia.7-, and 
TL.2-. A unique antigen was defined on the BALB/c ascites sarcoma Meth A 
with antisera prepared in BALB/c or (BALB/c ×  C57BL/6)F1 mice. Tissue cul- 
ture lines derived from this tumor were MuLV-, which facilitated serological 
study of the antigen. Absorption analysis indicated that the antigen was re- 
stricted to Meth A; it could not be detected in normal or fetal BALB/c tissue, 
MuLV  + or  MuLV-  fibroblast lines,  12  syngeneic or  allogeneic sarcomas,  or 
normal lymphoid cells from 13 different inbred mouse strains. 
We wish to express our thanks to Dr. Elisabeth Stockert and Dr.  Herbert F.  Oettgen for advice 
and support, and to Dr. Paul V. O'Donnell for performing the XC plaque tests. 
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